betvisa ph
Who to start in fantasy football: Week 14 rankings, start-sit advice, sleepers for PPR leagues | Sporting News
NoneDifferent political leaders from the ruling Pakistan Muslim League-Nawaz (PML-N) have strongly criticised Bushra Bibi's recent statement alleging Saudi Arabia's involvement in the ouster of former Prime Minister Imran Khan in 2022, stressing the importance of maintaining respectful and strategic foreign relations. Condemnation from the PML-N leaders came after the PTI founder's better half, in a rare video message issued on Thursday, accused Saudi Arabia of playing a role in toppling the Imran Khan-led government in 2022. Deputy Prime Minister and Foreign Minister Ishaq Dar expressed dismay over the statement, saying, "Targeting Saudi Arabia for political gains is regrettable. The statement reflects a desperate mindset." He urged political forces to refrain from compromising foreign policy for their objectives, highlighting the brotherly relations between Pakistan and Saudi Arabia, which are based on mutual respect. "We take pride in Saudi Arabia's journey of progress and prosperity," Dar added, noting that Saudi Arabia has supported Pakistan in difficult times. Reacting to Bushra Bibi's statement, Defence Minister Khawaja Asif denounced the Pakistan Tehreek-e-Insaf (PTI), which the minister said has now started using religion for personal gain. The minister added that the former ruling party could go to any length to gain political mileage. "Now they have started playing the Shariah card," he remarked, criticising the exploitation of religious sentiments to gain political advantage. Punjab Information Minister Azma Bukhari termed the former first lady’s remarks a “suicidal attack” on a friendly Islamic country. "These troublemakers cannot bring any good to the country," she said, stressing the dangerous implications of such accusations against Saudi Arabia which she described as “a pillar of the Muslim Ummah”. Meanwhile, Information Minister Atta Tarar condemned Bushra Bibi's statement, pointing out the irony of her accusations against a country where her daughter was married. "The same country gave them gifts, which Bushra Bibi sold in the black market," he claimed, calling her allegations "extremely filthy." Chairman of the Pakistan Ulema Council, Allama Tahir Ashrafi, dismissed Bushra Bibi's statement as baseless, recalling the respect and generosity shown by Saudi Arabia during Imran Khan's visit to the country. "I was present during the visit, and General Bajwa was also there. The delegation received great respect in Saudi Arabia," he said. Ashrafi questioned the basis of Bushra Bibi's claims, asserting that Islamic laws were firmly in place in Saudi Arabia. “Which Shariah did the PTI founder enact in Pakistan? And, what threat did it pose to Saudi Arabia?” he questioned. "The real issue is that Saudi Arabia is investing in Pakistan,” Ashrafi said, adding that a certain group is spreading propaganda against the friendly Islamic country. "This is an attempt to appease the forces hostile to Saudi Arabia," he added.Google announces quantum computing chip breakthroughNovae Stone Investment, a prominent real estate investment firm, is contributing to the development of the Columbia City Project 12-09-2024 10:16 PM CET | Business, Economy, Finances, Banking & Insurance Press release from: ABNewswire The new seven-story condominium tower is one of the largest residential projects in Seattle. Image: https://www.abnewswire.com/uploads/3fe0d75064c93dc933c831375c8cd688.png Novae Stone Investment [ https://novae-stone.com/portfolio/columbia-city-project/ ], a leading investment group, is excited to be playing a part in the development of the upcoming Columbia City Project. The new seven-story condominium tower will be one of the largest residential projects in Seattle, WC, with more than 260 residential units located on a site of more than 30,000 square feet. The global asset management company, which specializes in high-growth investments, saw the potential in the Columbia City Project after doing in-depth research on the dynamics of the market. As one of the leading economic centres in Washington State, Seattle has emerged as one of the biggest technology cities in the country. Talking to the media, a representative of the company said, "Seattle's real estate market has a lot of potential with dozens of Fortune 500 companies located in the area, including Costco, Expedia, Boeing, Microsoft, and Amazon. Moreover, there are two major Army and Air Force and military bases present in Lakewood, a city south of Seattle. It's also one of the biggest export states for various crops, including wines. All these factors ensure that the outlook for the project will remain stable in the present and long term. The new development will also bring a new level of luxury and development to the area and has attracted interest from residents in the area and across the country." The project is being developed by GI Group LLC, the developer of project, and features a range of amenities designed to enhance the living experience for residents. These amenities include one level of underground parking, providing residents with secure and convenient parking options. The second phase of the project related to construction began in November 2021, with the construction of the 260-unit East Building to be completed later this year and leasing to start at the end of 2023. People who invested in the Columbia City Phase II Building Fund will start receiving their return under the profit distribution model when the project is sold out after holding it for five years. The investment company will also assist in tax planning and future asset allocations for its clients. For media inquiries, please contact Sarah Ross from Novae Stone Investment at info@novae-stone.com or visit http://www.novae-stone.com Investors interested in learning more about the project can visit their website to get a detailed breakdown of the financials of the company. https://novae-stone.com/portfolio/columbia-city-project/ . Media Contact Company Name: Novae Stone Investment Contact Person: Sarah Ross Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=novae-stone-investment-a-prominent-real-estate-investment-firm-is-contributing-to-the-development-of-the-columbia-city-project ] Country: United States Website: http://novae-stone.com/portfolio/columbia-city-project/ This release was published on openPR.
Pembina Pipeline Corporation Announces Redemption of Series 22 Preferred SharesNew York takes on St. Louis after Panarin’s 2-goal showing
Lam Research Corporation Comments on Newly Announced Export Regulations
Different political leaders from the ruling Pakistan Muslim League-Nawaz (PML-N) have strongly criticised Bushra Bibi's recent statement alleging Saudi Arabia's involvement in the ouster of former Prime Minister Imran Khan in 2022, stressing the importance of maintaining respectful and strategic foreign relations. Condemnation from the PML-N leaders came after the PTI founder's better half, in a rare video message issued on Thursday, accused Saudi Arabia of playing a role in toppling the Imran Khan-led government in 2022. Deputy Prime Minister and Foreign Minister Ishaq Dar expressed dismay over the statement, saying, "Targeting Saudi Arabia for political gains is regrettable. The statement reflects a desperate mindset." He urged political forces to refrain from compromising foreign policy for their objectives, highlighting the brotherly relations between Pakistan and Saudi Arabia, which are based on mutual respect. "We take pride in Saudi Arabia's journey of progress and prosperity," Dar added, noting that Saudi Arabia has supported Pakistan in difficult times. Reacting to Bushra Bibi's statement, Defence Minister Khawaja Asif denounced the Pakistan Tehreek-e-Insaf (PTI), which the minister said has now started using religion for personal gain. The minister added that the former ruling party could go to any length to gain political mileage. "Now they have started playing the Shariah card," he remarked, criticising the exploitation of religious sentiments to gain political advantage. Punjab Information Minister Azma Bukhari termed the former first lady’s remarks a “suicidal attack” on a friendly Islamic country. "These troublemakers cannot bring any good to the country," she said, stressing the dangerous implications of such accusations against Saudi Arabia which she described as “a pillar of the Muslim Ummah”. Meanwhile, Information Minister Atta Tarar condemned Bushra Bibi's statement, pointing out the irony of her accusations against a country where her daughter was married. "The same country gave them gifts, which Bushra Bibi sold in the black market," he claimed, calling her allegations "extremely filthy." Chairman of the Pakistan Ulema Council, Allama Tahir Ashrafi, dismissed Bushra Bibi's statement as baseless, recalling the respect and generosity shown by Saudi Arabia during Imran Khan's visit to the country. "I was present during the visit, and General Bajwa was also there. The delegation received great respect in Saudi Arabia," he said. Ashrafi questioned the basis of Bushra Bibi's claims, asserting that Islamic laws were firmly in place in Saudi Arabia. “Which Shariah did the PTI founder enact in Pakistan? And, what threat did it pose to Saudi Arabia?” he questioned. "The real issue is that Saudi Arabia is investing in Pakistan,” Ashrafi said, adding that a certain group is spreading propaganda against the friendly Islamic country. "This is an attempt to appease the forces hostile to Saudi Arabia," he added.This holiday season, be thankful for the taxpayer protections we have in California
Join our newsletter to get the latest military space news every Tuesday by veteran defense journalist Sandra Erwin. HELSINKI — China is developing a dependence on space-based space situational awareness as its space activities expand, according to a new report. China’s on-orbit presence has grown dramatically in recent years, with a boom in numbers of satellites launched, and the construction of the Tiangong space station. However, its space situational awareness (SSA) architecture heavily relies on space-based systems due to its limited global ground sensor network, according to a report from the China Aerospace Studies Institute (CASI). The report provides new insights into China’s SSA infrastructure and outlines its unique constraints and priorities. China has sent at least 10 spacecraft to low Earth orbit (LEO) for space-based SSA, according to analysis of open-source Chinese reports and literature. Further unspecified satellites in general orbits have been referred to texts as carrying out SSA tasks. Noted satellites include Shiyan and Shijian technology demonstration spacecraft, as well as satellites from commercial actors Changguang Satellite Technology , operator of the Jilin remote sensing constellation, and Origin Space , a space resources firm. The satellites use mostly optical (including infrared for detecting heat sources, especially useful when spacecraft are in Earth’s shadow, and LiDAR) and radio frequency sensors, with a variety of detection ranges. Chinese satellites employ onboard processing for tasks like collision avoidance, aiming to reduce reliance on limited and overburdened ground stations. This autonomy enables faster response times, crucial for a nation with limited access to global relay networks. The general U.S. approach is described as relying on data analysis on the ground with human oversight. LEO is currently the main focus of its SSA efforts due to the dense satellite population and collision risks. Less attention is set on geostationary orbit, on which the U.S. has a stronger focus. The development of China’s space-based SSA is seen not only as having military uses and applications, but also for collision avoidance and other strategic and economic reasons. The efforts also assist China’s aim of building its own space object catalog, rather than relying on U.S. or Russian data. Traditional methods for tracking and identifying satellites are falling behind as space grows more crowded, leaving critical gaps and uncertainties. HEO’s flyby NEI is changing that, offering rapid satellite identification and characterisation. Explore our latest white paper &... pic.twitter.com/I9QhIPLpuf — HEO (@heospace) December 2, 2024 China’s approach is found to contrast with that of the U.S., which integrates space-based SSA with extensive ground sensors. China’s ability to establish ground sensors is limited by political factors. These divergent approaches bring potential challenges and opportunities, the report states. China’s reliance on space-based SSA assets could heighten threat perceptions if these systems are disrupted, potentially leading to misinterpretation of incidents. Conversely, the report suggests, this dependence may also drive China’s commitment to space stability, given its growing reliance on space for economic and military operations. The report also recommends that the U.S. regulators expedite the process to allow companies to supply non-Earth imagery in higher orbits to remain competitive with Chinese companies. The building of China’s comprehensive space object catalog could also have implications. It may rival the U.S. Space-track system and serve as an alternative for global users, potentially reducing U.S. influence in space traffic management. China’s need for SSA, a catalog and collision avoidance is growing. China had more than 900 satellites in orbit by mid-July this year, according to China Central Television (CCTV). The country has launched over 230 spacecraft across 62 orbital launch attempts so far in 2024. 54 of these have been for the Qianfan/Thousand Sails megaconstellation, while the first satellites for the national Guowang constellation could launch on a Long March 5B rocket this week. Together, the constellations plan to send more than 27,000 satellites into orbit. The sheer scale of these constellations underscores China’s ambition but also presents challenges for space traffic management and debris mitigation, necessitating robust SSA systems. SpaceX meanwhile already has more than 5,000 satellites in orbit for its Starlink constellation, underscoring the complex, global nature of space traffic management challenges ahead. Chinese researchers earlier this year called for expanded SSA capabilities .Add a festive touch to every visit with Reolink's Holiday-themed quick replies! Whether it's being away from home, welcoming friends, receiving deliveries, or turning away unwanted visitors, Reolink doorbells offer fun and thoughtful quick replies for every situation, spreading warmth and joy while keeping the doorstep secure. One of the recommendations is Reolink Doorbell WiFi , a smart 2K dual-band Wi-Fi doorbell with a full head-to-toe view. This doorbell makes everyday life easier and safer, with crystal-clear video to capture every detail at the front door, two-way audio for convenient conversations, and smart alerts to protect the security of deliveries during this busy holiday season. Now grab this exceptional doorbell at a 29 % discount, available for $ 127 .99 . Gifts that Keep Your Loved Ones Safe Reolink also highlights its top-tier security cameras as ideal Christmas gifts for safeguarding loved ones and homes. Argus 4 Pro is an advanced 4K battery-powered camera with 180° all-around view. With innovative ColorX technology, it ensures clear and detailed views both day and night. This camera helps monitor the entire yard, offering peace of mind by keeping an eye on the property, even when the home is unoccupied during the holidays. Now available at a 23% discount, stands at $ 254.99. E1 Zoom is an indoor 5MP PTZ camera with person/pet detection and auto tracking capability. Whether it's keeping an eye on kids playing in the living room, automatically tracking the movement of a pet as it roams the house, or ensuring everything is secure when family members are away, this camera provides peace of mind. This camera also adds two more features of cry detection and privacy mode, which will available gradually over the next few weeks. Now available at a 25% discount, stands at $ 97 .99 . Join #reocap Fun Reolink not only offers amazing security camera deals this holiday season but also invites everyone to join the Reocap Challenge on social media from now to 20 th December , for a chance to win Reolink's latest innovative cameras. Capture the magic moments of the holidays with Reolink cameras and just simply share them on social media (Instagram, TikTok, Youtube, X, or Facebook), tag with #reocap. Celebrate the season, enjoy unbeatable deals at Reolink.com and Amazon , and share unforgettable stories with #reocap today! About Reolink Reolink offers smart security solutions for homes and businesses, aiming for a seamless security experience with its wide range of products. Serving millions globally, it provides video surveillance and protection, standing out for its commitment to security technology innovation.
Labour's 'dangerously misguided foreign policy' threatens special relationship with USChina is building on-orbit space situational awareness capabilities to navigate crowded orbits
All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach 6-Month Follow-up Remains in DORIS Clinical Remission and Free of All Immunosuppressive Therapies Company Plans to Initiate Dose Expansion at First Dose Level of 360M Cells SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today presented new clinical and translational data from the Company's FT819 Phase 1 Autoimmunity study for moderate-to-severe systemic lupus erythematosus (SLE) at the American Society of Hematology (ASH) Annual Meeting being held in San Diego, CA. The first three study patients, each of whom presented with active lupus nephritis (LN) despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning followed by a single dose of FT819 at 360 million cells. There were no dose-limiting toxicities (DLTs), no events of any grade of cytokine release syndrome (CRS), immune effector-cell associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GvHD), and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. FT819 is the Company's off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking. "We continue to be very pleased with early clinical observations of fludarabine-free conditioning and FT819 off-the-shelf, CAR T-cell therapy in patients with moderate-to-severe SLE. The remarkable experience of the first patient treated in April is ongoing, as the patient remains on-study in drug-free clinical remission. In addition, the initial clinical and translational data from the two additional patients treated at the first dose level continue to support the potential for disease transformation,” said Bob Valamehr, President of Research and Development of Fate Therapeutics. "We are now initiating dose expansion at this first dose level to accelerate development, and are also escalating dose based on the favorable safety profile observed. In addition, I am pleased to announce that the first patient has now been treated with FT819 as an add-on to maintenance therapy without conditioning chemotherapy. We believe our therapeutic approach is highly-differentiated and has the potential to transform disease outcomes without requiring patient apheresis, discontinuation of maintenance therapy, intense conditioning chemotherapy, and extended hospitalization.” FT819 Phase 1 Autoimmunity Study The ongoing multi-center, Phase 1 clinical trial for patients with moderate-to-severe SLE is designed to evaluate the safety, pharmacokinetics, and anti-B cell activity of FT819 (NCT06308978). The first three patients, all of whom presented with active LN despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning consisting of either cyclophosphamide alone or bendamustine alone, followed by a single dose of FT819 at 360 million cells. In all three patients, FT819 was detected in the peripheral blood and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. All three patients remain on-study, and there have been no DLTs and no events of any grade of CRS, ICANS, or GvHD. Based on these clinical observations, the Company is initiating dose expansion in up to 10 patients at this first dose level, and is also escalating dose to 720 million cells. The Company's FT819 Phase 1 Autoimmunity study also includes a second treatment arm to assess the safety, pharmacokinetics, and anti-B cell activity of a single dose of FT819 as an add-on to maintenance therapy without conditioning chemotherapy in patients with SLE. The first patient has now been treated in this second arm, which is being conducted in parallel with the study's conditioning arm. FT819 Patient 1 Case Study The first patient treated in the Phase 1 Autoimmunity study presented with active LN and severe disease, which was marked by renal BILAG A (British Isles Lupus Assessment Group) disease activity score based on biopsy, SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index) score of 20, FACIT-Fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue) score of 33 (range 0-52, where a score of 52 indicates no fatigue) and PGA (Physician Global Assessment) score of 2.5 (where a score of 3 indicates most severe activity). Following administration of fludarabine-free conditioning and treatment with a single dose of FT819 at 360 million cells, the patient was discharged from the hospital without notable adverse events (AEs) after a protocol-required three-day stay. Rapid elimination of CD19+ B cells in the periphery was observed following treatment, and B-cell recovery by Month 3 was predominantly comprised of naïve, non-class switched B cells with near-complete elimination of switched memory B cells and deep depletion of plasmablasts, indicative of an immune reset. The patient reported that her debilitating fatigue had entirely resolved without further treatment, and treatment with methylprednisolone was discontinued at Month 3. The patient achieved DORIS (definition of remission in SLE) clinical remission, including with resolution of arthritis and active urinary sediment and with a substantial reduction in proteinuria, as of Month 6 follow-up. The patient continues on-study, in DORIS clinical remission, and remains free of all immunosuppressive therapy. iPSC-derived CAR T-cell Product Platform The Company also highlighted the scientific progress of its proprietary iPSC-derived CAR T-cell product platform at the ASH Annual Meeting. In an oral presentation entitled " Off-the-shelf Product Candidate Incorporates Novel Sword & Shield Technology Designed to Promote Functional Persistence without Conditioning Chemotherapy ”, the Company compared its novel Sword & Shield technology, which utilizes a 4-1BB-targeted CAR (ADR) alongside the complete knock-out of CD58 (CD58KO) to both target and evade host alloreactive immune cells, to other host immune evasion strategies. In preclinical studies of allogeneic models, the Company showed that its Sword and Shield Technology specifically engaged with alloreactive T cells and supported functional persistence while avoiding the killing of general host T cells and activated anti-tumor T cells. This unique observation was not seen with other approaches that are either too broad and undesirably eliminate most of the host immune system or have limited coverage and cannot adequately protect the allogeneic cell product. In a second presentation entitled " Development of Induced Pluripotent Stem Cell-Derived T Cells Exhibiting Phenotypic and Functional Attributes of Primary CAR T Cells ”, the Company conducted a series of high-resolution analyses to show stimulated iPSC-derived T cells elicit primary T-cell like activation, proliferation, transcriptional and functional program engagement, and iPSC-derived CAR T cells uniquely emulate antigen-mediated response similar to primary-derived autologous CAR T cells. About Fate Therapeutics' iPSC Product Platform Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company's proprietary iPSC product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be combined and administered with other therapies, and can potentially reach a broad patient population. As a result, the Company's platform is uniquely designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Fate Therapeutics' iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications. About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company's pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com . Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the safety and therapeutic potential of the Company's iPSC-derived CAR T-cell product candidates, including FT819, the advancement of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the Company's progress, plans and timelines for the clinical investigation of its product candidates, including the expected clinical development plans for FT819, the initiation and continuation of enrollment in the Company's clinical trials, the initiation of additional clinical trials and additional dose cohorts in ongoing clinical trials of the Company's product candidates, the timing and availability of data from the Company's clinical trials, the therapeutic and market potential of the Company's research and development programs and product candidates, the Company's clinical and product development strategy, and the Company's expectations regarding progress, plans, and timelines. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company's research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company's product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company's product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company's ongoing and planned clinical trials, difficulties or delays in manufacturing or supplying the Company's product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company's periodic filings with the Securities and Exchange Commission, including but not limited to the Company's most recently filed periodic report, and from time to time in the Company's press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. Contact: Christina Tartaglia Precision AQ 212.362.1200 [email protected]C$ unless otherwise stated TSX/NYSE/PSE: MFC SEHK: 945 TORONTO , Dec. 9, 2024 /PRNewswire/ - Manulife has been notified of an unsolicited mini-tender offer made by New York Stock and Bond LLC (New York Stock and Bond) to purchase up to 50,000 Manulife common shares, or less than 0.003% of the common shares outstanding, at a price of USD$12.50 per share. Manulife is in no way associated with New York Stock and Bond and does not recommend or endorse acceptance of this unsolicited offer. Manulife cautions shareholders that the mini-tender offer has been made at a price below the current market price for Manulife shares. The offer represents a discount of approximately 60.76% and 60.80%, respectively, below the closing prices of Manulife common shares on the TSX and NYSE on November 27, 2024 , the last trading day before the mini-tender offer was commenced, and a discount of 61.43% and 61.42%, respectively, below the closing prices on the TSX and NYSE on December 6, 2024 . Mini-tender offers are designed to seek less than 5% of a company's outstanding shares, avoiding disclosure and procedural requirements applicable to most bids under Canadian and U.S. securities regulations. The Canadian Securities Administrators (CSA) and the U.S. Securities and Exchange Commission (SEC) have expressed serious concerns about mini-tender offers, including the possibility that investors might tender to such offers without understanding the offer price relative to the actual market price of their securities. The SEC states that "bidders make mini-tender offers at below-market prices, hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price." Shareholders should carefully review the New York Stock and Bond offer documents and current market price for Manulife shares, and consult their investment advisors regarding any offer they may receive and review with their advisors all options for their investment in Manulife shares. Manulife has stock transfer agents providing shareholder services in Canada , the United States , Hong Kong and the Philippines . These local agents provide services directly to our registered shareholders and can provide information on share account management, direct deposit of dividends, dividend reinvestment and share purchase plans. Please email manulifeinquiries@tmx.com for more information. Manulife requests that a copy of this news release be included in any distribution of materials relating to New York Stock and Bond's mini-tender offer for Manulife common shares. About Manulife Manulife Financial Corporation is a leading international financial services provider, helping people make their decisions easier and lives better. With our global headquarters in Toronto, Canada , we provide financial advice and insurance, operating as Manulife across Canada , Asia , and Europe , and primarily as John Hancock in the United States . Through Manulife Investment Management, the global brand for our Global Wealth and Asset Management segment, we serve individuals, institutions, and retirement plan members worldwide. At the end of 2023, we had more than 38,000 employees, over 98,000 agents, and thousands of distribution partners, serving over 35 million customers. We trade as 'MFC' on the Toronto , New York , and the Philippine stock exchanges, and under '945' in Hong Kong. Not all offerings are available in all jurisdictions. For additional information, please visit manulife.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/manulife-cautions-investors-regarding-new-york-stock-and-bond-llc-offer-for-shares-302326646.html SOURCE Manulife Financial Corporation
Brainy, 'normal guy': the suspect in US insurance CEO's slayingHere's How Much $100 Invested In Imperial Oil 5 Years Ago Would Be Worth TodayLos Angeles Kings (11-7-3, in the Pacific Division) vs. San Jose Sharks (6-12-5, in the Pacific Division) San Jose, California; Monday, 10:30 p.m. EST BOTTOM LINE: The San Jose Sharks take on the Los Angeles Kings as losers of three games in a row. San Jose has a 6-12-5 record overall and a 1-5-0 record in Pacific Division games. The Sharks have a 2-6-1 record when they serve more penalty minutes than their opponent. Los Angeles is 4-4-0 against the Pacific Division and 11-7-3 overall. The Kings serve 9.9 penalty minutes per game to rank eighth in league play. The matchup Monday is the third meeting between these teams this season. The Sharks won 4-2 in the last matchup. TOP PERFORMERS: Mikael Granlund has nine goals and 15 assists for the Sharks. Macklin Celebrini has over the last 10 games. Alex Laferriere has scored nine goals with six assists for the Kings. Kyle Burroughs has over the last 10 games. LAST 10 GAMES: Sharks: 3-4-3, averaging 2.4 goals, 4.6 assists, three penalties and 6.6 penalty minutes while giving up 2.6 goals per game. Kings: 5-4-1, averaging 2.7 goals, 5.3 assists, 3.6 penalties and nine penalty minutes while giving up 1.7 goals per game. INJURIES: Sharks: None listed. Kings: None listed. ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar . The Associated Press
Cowboys end five-game losing streak with thrilling 34-26 upset of CommandersInvestigator finds Colorado voter system passwords were not intentionally posted onlineAidan Bouman, Quaron Adams rally South Dakota past Tarleton State 42-31 in FCS second-round duel
AKRON, Ohio (AP) — Bowen Hardman had 20 points in Akron's 101-48 victory NCAA-Division III-member SUNY-Brockport on Saturday. Hardman went 8 of 14 from the field (4 for 10 from 3-point range) for the Zips (6-2). James Okonkwo scored 12 points and added 16 rebounds. Nate Johnson shot 5 for 8, including 2 for 4 from beyond the arc to finish with 12 points, while adding six rebounds. The Golden Eagles were led in scoring by Tony Arnold, who finished with 11 points and eight rebounds. Jacob Oka added six points for SUNY-Brockport. Christian Amica also had five points. Akron took the lead with 18:22 left in the first half and never looked back. The score was 56-24 at halftime, with Hardman racking up 12 points. Akron outscored SUNY-Brockport by 21 points over the final half, while Evan Wilson led the way with a team-high eight second-half points. Akron visits Milwaukee in its next matchup on December 15. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .The Changing Market Dynamics of Immune Thrombocytopenia, Aplastic Anemia, and Diamond-Blackfan Anemia | DelveInsight InsightsObama Slammed for 'Hypocritical' First Post-Election Speech
NoneAir Force secures 69-61 win against Stony BrookLOUISVILLE, Ky. (AP) — Landin Hacker scored 21 points as Bellarmine beat NAIA-member Brescia 94-66 on Saturday. Hacker finished 7 of 11 from 3-point range for the Knights (3-7). Ben Johnson scored 17 points while going 6 of 13 (5 for 12 from 3-point range) and added six assists. Dylan Branson shot 5 of 7 from the field and 2 for 3 from the line to finish with 12 points, while adding 10 rebounds. Damian Garcia led the way for the Bearcats with 27 points. Gonzalo Luque added nine points, eight rebounds and five assists for Brescia. John Seanz also had eight points and two steals. Both teams next play Saturday. Bellarmine hosts Ball State and Brescia goes on the road to play Cleveland State. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .
NonePhiladelphia takes on Vegas after overtime winVictory Capital Management Inc. increased its stake in Robinhood Markets, Inc. ( NASDAQ:HOOD – Free Report ) by 85.3% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 117,383 shares of the company’s stock after acquiring an additional 54,046 shares during the quarter. Victory Capital Management Inc.’s holdings in Robinhood Markets were worth $2,749,000 at the end of the most recent reporting period. Several other hedge funds also recently modified their holdings of HOOD. HM Payson & Co. increased its stake in shares of Robinhood Markets by 53.5% in the 3rd quarter. HM Payson & Co. now owns 1,176 shares of the company’s stock valued at $28,000 after acquiring an additional 410 shares in the last quarter. Eastern Bank bought a new stake in shares of Robinhood Markets in the 3rd quarter valued at $30,000. ORG Partners LLC bought a new stake in shares of Robinhood Markets in the 2nd quarter valued at $33,000. ORG Wealth Partners LLC bought a new stake in shares of Robinhood Markets in the 3rd quarter valued at $33,000. Finally, International Assets Investment Management LLC bought a new stake in shares of Robinhood Markets in the 2nd quarter valued at $40,000. Institutional investors own 93.27% of the company’s stock. Analyst Upgrades and Downgrades HOOD has been the topic of several research reports. Citigroup upped their price objective on shares of Robinhood Markets from $19.00 to $23.00 and gave the stock a “neutral” rating in a report on Friday, September 27th. Bank of America upped their target price on shares of Robinhood Markets from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Barclays lifted their price target on Robinhood Markets from $23.00 to $26.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Deutsche Bank Aktiengesellschaft increased their price objective on Robinhood Markets from $27.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. Finally, KeyCorp raised their target price on Robinhood Markets from $25.00 to $30.00 and gave the company an “overweight” rating in a report on Monday, October 21st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Robinhood Markets presently has an average rating of “Moderate Buy” and a consensus target price of $28.66. Robinhood Markets Trading Up 4.4 % Shares of Robinhood Markets stock opened at $36.65 on Friday. The business’s fifty day simple moving average is $26.96 and its 200 day simple moving average is $22.96. The firm has a market capitalization of $32.40 billion, a P/E ratio of 62.12, a price-to-earnings-growth ratio of 0.82 and a beta of 1.84. Robinhood Markets, Inc. has a 12 month low of $8.13 and a 12 month high of $38.11. Robinhood Markets ( NASDAQ:HOOD – Get Free Report ) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The business had revenue of $637.00 million for the quarter, compared to the consensus estimate of $660.53 million. Robinhood Markets had a return on equity of 7.52% and a net margin of 21.80%. The business’s revenue was up 36.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.09) earnings per share. Analysts predict that Robinhood Markets, Inc. will post 0.74 EPS for the current fiscal year. Insider Buying and Selling In other Robinhood Markets news, Director Meyer Malka sold 105,875 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $30.00, for a total value of $3,176,250.00. Following the sale, the director now directly owns 28,930,243 shares in the company, valued at $867,907,290. The trade was a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website . Also, Director Baiju Bhatt sold 139,916 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $19.55, for a total value of $2,735,357.80. The disclosure for this sale can be found here . Over the last three months, insiders have sold 4,710,549 shares of company stock worth $115,477,194. 19.95% of the stock is owned by company insiders. Robinhood Markets Profile ( Free Report ) Robinhood Markets, Inc operates financial services platform in the United States. Its platform allows users to invest in stocks, exchange-traded funds (ETFs), American depository receipts, options, gold, and cryptocurrencies. The company offers fractional trading, recurring investments, fully-paid securities lending, access to investing on margin, cash sweep, instant withdrawals, retirement program, around-the-clock trading, and initial public offerings participation services. Featured Articles Five stocks we like better than Robinhood Markets When to Sell a Stock for Profit or Loss Vertiv’s Cool Tech Makes Its Stock Red-Hot How to Capture the Benefits of Dividend Increases MarketBeat Week in Review – 11/18 – 11/22 How to Invest in the FAANG Stocks 2 Finance Stocks With Competitive Advantages You Can’t Ignore Receive News & Ratings for Robinhood Markets Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Robinhood Markets and related companies with MarketBeat.com's FREE daily email newsletter .
None
Amanda Rishworth on tackling gender-based violence – Australian politics podcast